# Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles

Source: https://onco.cc/ideas/idea-moon-cachexia-as-treatable-disease/  
OnCo record `idea-moon-cachexia-as-treatable-disease` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The wasting that kills many cancer patients has had no effective drug. New antibodies against GDF-15 restored weight in early trials. Combine them with exercise and nutrition and test properly.

## Summary

Cancer cachexia affects a large share of patients with pancreatic, lung and gastric cancer and contributes directly to death and treatment intolerance. Ponsegromab, an anti-GDF-15 antibody, increased weight and activity in a randomised phase 2 trial; ghrelin agonists (anamorelin) are approved in Japan. The proposal is a programme treating cachexia as an indication in its own right: standardised diagnosis and staging, a phase 3 of GDF-15 blockade with function and survival endpoints, and multimodal bundles combining pharmacotherapy with resistance exercise and nutritional support, embedded early in oncology care rather than at end of life.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Early multimodal cachexia treatment improves physical function and chemotherapy completion and extends overall survival in pancreatic and lung cancer by a clinically meaningful margin.
- Rationale: Cachexia is mechanistically driven (GDF-15, inflammation, anorexia signalling) rather than an inevitable consequence, and the first mechanism-based drug has shown activity.
- Proposed test: Phase 3 of GDF-15 blockade plus multimodal support versus standard care in newly diagnosed metastatic pancreatic and lung cancer with cachexia; endpoints weight, function, chemotherapy dose intensity and survival.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011): https://doi.org/10.1016/S1470-2045(10)70218-7

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Definition and classification of cancer cachexia: an international consensus](https://onco.cc/key-papers/paper-fearon-lancet-oncol/)
- roadmaps: [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-cachexia-as-treatable-disease.json